SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Exclusion Criteria

• •1. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms.
• •2. Previous or co-existing malignancies.
• •3. Current or History of ILD.
• •4. Clinical symptoms or diseases of the heart that are not well controlled.
• •5. Arterial/venous thrombosis events occurred before the first dose.
• •6. Grade ≥2 bleeding events of CTCAE occurred before the first dose.
• •7. Gastrointestinal perforation or fistula, urethral fistula, abdominal abscess occurred before the first dose.
• •8. Patients with intestinal obstruction or parenteral nutrition before the first dose.
• •9. Serious infection before the first dose.
• •10. Active hepatitis B or active hepatitis C.
• •11. Received systemic anticancer treatments 4 weeks prior to the initiation of the study treatment.
• •12. Treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload.
• •13. Unresolved CTCAE ≥grade 2 toxicities from previous anticancer therapy.
• •14. History of severe hypersensitivity reactions to either the drug substances or inactive ingredients of SHR-A1921.
• •15. Other inappropriate situation considered by the investigator.